Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kolon Ramps Up For Novel Osteoarthritis Cell Therapy

This article was originally published in PharmAsia News

Executive Summary

South Korea's Kolon Life Science is gearing up for mass production of Invossa, the world's first cell-mediated gene therapy for osteoarthritis, as it prepares to file for a domestic approval and a US Phase III study. The venture also plans to raise around $114m to hike its biologics production capacity.

Advertisement

Related Content

Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
New Funding To Give ViroMed ‘Favorable Position’ For Gene Therapy Deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC089470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel